ReviewThe Prostate2013
Epigenetic susceptibility factors for prostate cancer with aging.
Review in The Prostate, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Association of glutathione-S-transferase p1 gene promoter methylation and the incidence of prostate cancer: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2019Pooled it
- Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies.The Journal of urology · 2014Trial
- Advanced age increases cancer-specific mortality in bone-only metastatic prostate cancer: a SEER analysis.Scientific reports · 2026Article
- Inflammaging: Immune-Metabolic Crosstalk Between the Prostate-Testis and Musculoskeletal System.International journal of molecular sciences · 2026Review
- RASSF1A and its epigenetic dysregulation in genitourinary cancer: a current update.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Social genomics and cancer - untangling nature from nurture in squamous cell carcinoma outcomes.Frontiers in oncology · 2026Review
- Molecular Landscape of Prostate Cancer Across Age Groups: Impact on Prognosis and Treatment Outcomes.International journal of molecular sciences · 2025Review
- α-lipoic acid modulates prostate cancer cell growth and bone cell differentiation.Scientific reports · 2024Article
- Article
- The Potential Role of Mitochondrial Acetaldehyde Dehydrogenase 2 in Urological Cancers From the Perspective of Ferroptosis and Cellular Senescence.Frontiers in cell and developmental biology · 2022Review
- Epigenomic regulation of human T-cell leukemia virus by chromatin-insulator CTCF.PLoS pathogens · 2021Article
- The Interplay Between Prostate Cancer Genomics, Metabolism, and the Epigenome: Perspectives and Future Prospects.Frontiers in oncology · 2021Review
- Elucidation of the Genomic-Epigenomic Interaction Landscape of Aggressive Prostate Cancer.BioMed research international · 2021Article
- CTCF loss mediates unique DNA hypermethylation landscapes in human cancers.Clinical epigenetics · 2020Article
- Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies.Clinical epigenetics · 2019Article
- Markers as mediators: A review and synthesis of epigenetics literature.BioSocieties · 2019Article
- CTCF regulates the FoxO signaling pathway to affect the progression of prostate cancer.Journal of cellular and molecular medicine · 2019Article
- PAGE4 promotes prostate cancer cells survive under oxidative stress through modulating MAPK/JNK/ERK pathway.Journal of experimental & clinical cancer research : CR · 2019Article
- Role of lncRNAs in aging and age-related diseases.Aging medicine (Milton (N.S.W)) · 2018Review
- Insulin-like growth factor 2 expression in prostate cancer is regulated by promoter-specific methylation.Molecular oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIncreasing age is a significant risk factor for prostate cancer. The prostate is exposed to environmental and endogenous stress that may underlie this remarkable incidence. DNA methylation, genomic imprinting, and histone modifications are examples of epigenetic factors known to undergo change in the aging and cancerous prostate. In this review we examine the data linking epigenetic alterations in the prostate with aging to cancer development.
methodsAn online search of current and past peer reviewed literature on epigenetic changes with cancer and aging was performed. Relevant articles were analyzed.
resultsEpigenetic changes are responsible for modifying expression of oncogenes and tumor suppressors. Several of these changes may represent a field defect that predisposes to cancer development. Focal hypermethylation occurs at CpG islands in the promoters of certain genes including GSTP1, RARβ2, and RASSF1A with both age and cancer, while global hypomethylation is seen in prostate cancer and known to occur in the colon and other organs. A loss of genomic imprinting is responsible for biallelic expression of the well-known Insulin-like Growth Factor 2 (IGF2) gene. Loss of imprinting (LOI) at IGF2 has been documented in cancer and is also known to occur in benign aging prostate tissue marking the presence of cancer. Histone modifications have the ability to dictate chromatin structure and direct gene expression.
conclusionsEpigenetic changes with aging represent molecular mechanisms to explain the increased susceptibly of the prostate to develop cancer in older men. These changes may provide an opportunity for diagnostic and chemopreventive strategies given the epigenome can be modified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.